Literature DB >> 17143611

Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.

Farah Aladin1, Georg Lautscham, Elizabeth Humphries, Judy Coulson, Neil Blake.   

Abstract

It is becoming increasingly apparent that the majority of tumours display defects in the MHC class I antigen processing pathway, particularly low levels of the transporters-associated with antigen processing (TAP) and tapasin. Thus, immunotherapy approaches targeting such tumours with CD8+ cytotoxic T lymphocytes (CTL) requires strategies to overcome these defects. Previously we had identified an antigen processing pathway by which cytosolically derived hydrophobic peptides could be presented in the absence of TAP. Here we show in the tapasin-negative cell line 721.220 that a number of these hydrophobic TAP-independent peptides can also be presented in a tapasin-independent manner. Yet when these experiments were extended to tumour cell lines derived from small cell lung cancer (SCLC), which we show to be tapasin deficient in addition to TAP-negative, the TAP-, tapasin-independent peptides were not presented. This lack of presentation could be rectified by pre-treatment of SCLC cells with IFNgamma. Alternatively, by directing the TAP-, tapasin-independent peptides into the endoplasmic reticulum (ER) via an ER signal sequence, these peptides were presented efficiently by SCLC cells. We infer from this data that the TAP-independent pathway for presentation of hydrophobic peptides generates a low concentration of peptide in the ER and, for tumour cells which also lack tapasin, this concentration of antigenic peptide is insufficient to load onto MHC class I molecules. Thus, for immunotherapeutic approaches to target SCLC and other tumours with defects in the MHC class I antigen processing pathway it will be important to consider strategies that address tapasin-defects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143611     DOI: 10.1007/s00262-006-0263-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  9 in total

1.  Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome.

Authors:  Qian Jiang; Hong-ya Pan; Dong-xia Ye; Ping Zhang; Lai-ping Zhong; Zhi-yuan Zhang
Journal:  Tumour Biol       Date:  2010-06-08

2.  Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Authors:  Nathalie Vigneron; Violette Ferrari; Benoît J Van den Eynde; Peter Cresswell; Ralf M Leonhardt
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

Review 3.  The use of signal peptide domains as vaccine candidates.

Authors:  Riva Kovjazin; Lior Carmon
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

4.  Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.

Authors:  Neil T Hoa; Lisheng Ge; Rajeev B Tajhya; Christine Beeton; Andrew N Cornforth; Amir Abolhoda; Nils Lambrecht; Maria DaCosta-Iyer; Yi Ouyang; Anthony P Mai; Erin Hong; Judy Shon; Michelle J Hickey; Kate L Erickson; Carol A Kruse; Martin R Jadus
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

5.  ERAAP and tapasin independently edit the amino and carboxyl termini of MHC class I peptides.

Authors:  Takayuki Kanaseki; Kristin Camfield Lind; Hernando Escobar; Niranjana Nagarajan; Eduardo Reyes-Vargas; Brant Rudd; Alan L Rockwood; Luc Van Kaer; Noriyuki Sato; Julio C Delgado; Nilabh Shastri
Journal:  J Immunol       Date:  2013-07-17       Impact factor: 5.422

Review 6.  Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.

Authors:  Martin R Jadus; Josephine Natividad; Anthony Mai; Yi Ouyang; Nils Lambrecht; Sandor Szabo; Lisheng Ge; Neil Hoa; Maria G Dacosta-Iyer
Journal:  Clin Dev Immunol       Date:  2012-07-29

7.  HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma.

Authors:  Camilla Thuring; Elna Follin; Linda Geironson; Eva Freyhult; Victoria Junghans; Mikkel Harndahl; Søren Buus; Kajsa M Paulsson
Journal:  Br J Cancer       Date:  2015-08-27       Impact factor: 7.640

8.  The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity.

Authors:  Gwendolin S Simper; Lareen S Gräser; Alexander A Celik; Joachim Kuhn; Heike Kunze-Schumacher; Gia-Gia T Hò; Rainer Blasczyk; Andreas Pich; Christina Bade-Doeding
Journal:  Pharmaceutics       Date:  2019-10-15       Impact factor: 6.321

9.  IFN-γ treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.

Authors:  Katja Stifter; Jana Krieger; Leonie Ruths; Johann Gout; Medhanie Mulaw; Andre Lechel; Alexander Kleger; Thomas Seufferlein; Martin Wagner; Reinhold Schirmbeck
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.